Informa
TIDES USA: Oligonucleotide & Peptide Therapeutics
2025年5月19-22日
米国、カリフォルニア州サンディエゴ、Manchester Grand Hyatt San Diego
Key Sessions
基調講演セッション
Kristy Wood, PhD
Realizing the Promise of CRISPR Therapeutics
Intellia Therapeutics
Hiroaki Suga, PhD
RaPID Display and Selection of Pseudo-natural Products
University of Tokyo
Art Levin, PhD
State of the Art: A Look at Oligonucleotide Therapeutics Past, Present, and Future
Avidity Biosciences
Lotte Bjerre Knudsen, PhD
The Science Behind the GLP-1 Medicines: A Historic View and Future Outlook
Novo Nordisk A/S
Muthiah (Mano) Manoharan, PhD
“I Love Conjugates”: The GalNAc Revolution and Its Impact on Oligonucleotide Therapeutic Development
Alnylam Pharmaceuticals
Sam Tsimikas, MD
Clinical Update on Oligonucleotides for Cardiovascular Disease
Ionis Pharmaceuticals

主要会議 - 1日目 基調講演セッション（5月20日）

search
6:30am - 7:30am60 mins
Registration
    Breakfast Spotlight Presentations
    7:30am - 8:00am30 mins
    Breakfast Spotlight Presentations 1
    Technical Application of Continuous Chromatography and Mixer-Type Lyophilization in Peptide and Oligonucleotide Downstream Processes
    • Yoshitaka Nemoto - Vice President R&D, PeptiStar
    7:30am - 8:00am30 mins
    Breakfast Spotlight Presentations 2
    LNP Production for mRNA Vaccines, Therapeutics, and for Gene Editing - Proof of Concept for a Versatile Process
    • Thomas Vrucina - Deputy Head Liposome Technology, Polymun Scientific
    7:30am - 8:00am30 mins
    Breakfast Spotlight Presentations 3
    Synthetic Peptide CMC Development and Experiences
    • Susan Li, PhD - Peptide Chief Scientist, Asymchem
    8:10am - 8:15am5 mins
    Keynote and Plenary Session
    Chairperson’s Remarks: Keynote Day 1
      8:15am - 9:00am45 mins
      Keynote and Plenary Session
      The Science Behind the GLP-1 Medicines: A Historic View and Future Outlook
      • Lotte Bjerre Knudsen, PhD - Chief Scientific Advisor & Head of GLP-1 CoE, Novo Nordisk A/S
      9:00am - 9:45am45 mins
      Keynote and Plenary Session
      “I Love Conjugates”: The GalNAc Revolution and Its Impact on Oligonucleotide Therapeutic Development
      • Muthiah (Mano) Manoharan, PhD - Senior Vice President of Drug Innovation and Distinguished Research Scientist, Alnylam Pharmaceuticals
      9:45am - 10:15am30 mins
      Networking Refreshment Break
        Morning Keynote Session
        10:15am - 11:00am45 mins
        Keynote and Plenary Session
        Realizing the Promise of CRISPR Therapeutics
        • Kristy Wood, PhD - SVP, Technical Operations, Intellia Therapeutics
        11:00am - 11:45am45 mins
        Keynote and Plenary Session
        Oligonucleotide Therapeutics: Current Challenges and Opportunities
        • David Corey, PhD - Professor of Pharmacology and Biochemistry, UT Southwestern; Past President, OTS
        11:45am - 12:05pm20 mins
        Transition to Spotlight Presentation/Panel Luncheons
          Spotlight Presentation Luncheons
          12:05pm - 12:35pm30 mins
          Spotlight Presentation Luncheon 1
          Biodegradable Lipid Nanoparticles with Tunable Immunogenicity
          • Syed Reza, MD, PhD - Scientific and Sales Consultant, NOF Corporation
          12:05pm - 12:35pm30 mins
          Spotlight Presentation Luncheon 2
          Novel Approaches to Minimize dsRNA in mRNA Production
          • Kevin Ou - Director, Product Strategy & Management - mRNA LNP, Aldevron
          12:05pm - 12:35pm30 mins
          Spotlight Presentation Luncheon 3
          Advancing mRNA Therapeutics: Novel Modification Strategies for Improved Performance
          • Chunping Xu, Ph.D - Senior Director of Chemistry R&D, TriLink BioTechnologies
          12:05pm - 12:35pm30 mins
          Spotlight Presentation Luncheon 4
          Nitto Avecia Spotlight Presentation
            12:05pm - 12:35pm30 mins
            Spotlight Luncheon Presentation 5
            Bachem Spotlight Presentation
            • Arne Berthelmann - Senior Director Oligonucleotide R&D, Bachem AG
            12:05pm - 12:35pm30 mins
            Spotlight Presentation Luncheon 6
            Axolabs Spotlight Presentation
              12:35pm - 12:55pm20 mins
              Short Networking Break
                Afternoon Keynote Session
                12:55pm - 1:00pm5 mins
                Keynote and Plenary Session
                Chairperson’s Remarks: Keynote Day 1
                  1:00pm - 1:45pm45 mins
                  Keynote and Plenary Session
                  State of the Art: A Look at Oligonucleotide Therapeutics Past, Present, and Future
                  • Art Levin, PhD - Retired CSO, Avidity Biosciences
                  1:45pm - 2:30pm45 mins
                  Keynote and Plenary Session
                  Clinical Update on Oligonucleotides for Cardiovascular Disease
                  • Sam Tsimikas, MD - Senior Vice President of Global Cardiovascular Development, Ionis Pharmaceuticals
                  2:30pm - 3:30pm60 mins
                  Grand Opening of Poster and Exhibit Halls (Grand Ballroom and Harbor Ballroom) and Networking Refreshment Break
                    3:30pm - 4:15pm45 mins
                    Keynote and Plenary Session
                    RaPID Display and Selection of Pseudo-natural Products
                    • Hiroaki Suga, PhD - Professor of Chemistry, School of Science, University of Tokyo
                    4:15pm - 5:00pm45 mins
                    Keynote and Plenary Session
                    Panel Discussion: Addressing the Challenges of Bringing New Therapeutic Modalities to Market: Technical and Regulatory Considerations
                    • Rachael Anatol - Deputy Super Office Director, Office of Therapeutic Products, CBER, FDA
                    5:00pm - 6:30pm90 mins
                    Networking Reception in Poster and Exhibit Halls (Grand Ballroom and Harbor Ballroom)
                      プレ会議（5月19日）
                      Next主要会議 - 2日目（5月21日）

                      * 不測の事態により、事前の予告なしにプログラムが変更される場合があります。